About Us

About Us


XyloCor Therapeutics is a biopharmaceutical company developing gene therapy for people with advanced coronary artery disease.  It was founded by Dr. Ronald Crystal and Dr. Todd Rosengart.  XyloCor is focused on developing its lead product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks.

founders and Board


 

Glenn Batchelder – Executive Chairman
Mr. Batchelder has over 20 years of experience in biotech.  He is the former co-founder and CEO of Civitas Therapeutics (sold to Acorda), former CEO of BIND Therapeutics (sold to Pfizer) and Acceleron Pharma (NASDAQ:XLRN).  Mr. Batchelder is also a past chairman of MassBio.

glenn-batchelder

Ronald Crystal, MD – Founder and Advisor
Dr. Crystal is Bruce Webster Professor and Chairman, Department of Genetic Medicine, Weill Cornell Medical College and Director of the Belfer Gene Therapy Core Facility.  He has been a leader in gene therapy for over 20 years and developed the FDA-approved therapy for alpha-1 antitrypsin deficiency.  Dr. Crystal is also the first to use a recombinant virus as a vehicle for in vivo gene therapy.

 

dr-crystal

Todd Rosengart, MD – Founder and Advisor 
Dr. Rosengart is Professor and DeBakey-Bard Chairman, Department of Surgery, Baylor Medical College; Professor of Heart and Vascular Disease at the Texas Heart Institute.  He has been a leading researcher in cardiac angiogenesis and regeneration for over 30 years and was the first US administration of adenovirus vector for cardiac gene transfer.  Dr. Rosengart is also co-founder of Vitals.com.

dr-rosengart

 

management


 al-gianchetti

Albert Gianchetti – President and CEO
Mr. Gianchetti has over 25 years of drug development and commercialization experience.  He has held executive level roles at GSK and additional leadership roles with small biotech and specialty pharma companies.  Mr. Gianchetti has extensive experience in both commercial strategy/operations and R&D including 7 Phase III programs, over 10 Phase I/II programs and several product launches.

howard-dittrichjeffrey-rudy

Howard Dittrich, MD – Chief Medical Advisor
Dr. Dittrich is a cardiologist and Adjunct Professor of Medicine and Chair of the Board of Directors of the François M. Abboud Cardiovascular Research Center at the University of Iowa Carver College of Medicine.  He has experience as a CMO at several biotechs including Hawkeye, NovaCardia, and Sequel.  Dr. Dittrich has extensive experience in regenerative medicine for CV disease.

Jeffrey Rudy – Clinical Operations
Mr. Rudy has extensive experience in clinical operations and study conduct at big pharma, biotechs and startups.  He was the clinical operations head at Celladon and has held senior level clinical operations positions at Pfizer and Anaborex.

 

Clare Kahn, PhD – Regulatory Affairs Consultant/Principal Clare Kahn Pharma Consulting LLC
Dr. Kahn is the Former Vice President of Global Regulatory Affairs Innovative Portfolio for Pfizer, Inc. She had VP roles for GSK Pharma and Biologicals. She was also a former Assistant Professor of Pharmacology for the University of Pennsylvania.

remi-gloeckler

Rémi Gloeckler, PhD – CMC Head
Dr Gloeckler has over 15 years of experience in quality and manufacturing leadership in gene therapy.  He was Transgene’s Vice President of pharmaceutical and industrial operations and then formed PharminCell in September 2011 where he has consulted for leading gene therapy companies.